Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,856 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acquired Immunodeficiency Syndrome Virus Clear all
Completed No phase listed Observational

Managerial Database II

NCT01322217
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection

NCT00001445
View directory record Official record
Conditions
HIV Infection
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

NCT03547245
View directory record Official record
Conditions
HIV/AIDS
Interventions
eOD-GT8 60mer + AS01B/ DPBS sucrose/IM, DPBS Sucrose
Biological
Lead sponsor
International AIDS Vaccine Initiative
Network
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 10, 2026, 4:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Immune Responses Toward HIV-1 Envelope Antigens

NCT01344941
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Using Open Contest and Neuro-influence Experiment to Develop and Evaluate PrEP Promotion Messages for High Risk Men

NCT04166851
View directory record Official record
Conditions
HIV/AIDS
Interventions
PrEP campaign messages developed via open contest, PrEP campaign messages developed via social marketing approach
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 10, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

NCT04272242
View directory record Official record
Conditions
HIV Infection, LTBI
Interventions
Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

NCT00091741
View directory record Official record
Conditions
HIV Infection
Interventions
Etanercept (Enbrel)
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

NCT00262522
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

NCT02741557
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
DTG, RPV, DTG/RPV FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

NCT00000788
View directory record Official record
Conditions
Candidiasis, HIV Infections
Interventions
Methadone hydrochloride, Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Culturally-Tailored HIV Risk Reduction for African-American MSM

NCT00691561
View directory record Official record
Conditions
HIV Infections
Interventions
Project ABLE
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

NCT02720094
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users

NCT01343654
View directory record Official record
Conditions
HIV Infections
Interventions
Text messaging plus EMA, Treatment as usual
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional

Dideoxycytidine ( Ro 24-2027 ). A Treatment Protocol for the Use of Dideoxycytidine ( ddC ) in Patients With AIDS or Advanced ARC Who Cannot Be Maintained on Zidovudine ( AZT ) Therapy.

NCT00002256
View directory record Official record
Conditions
HIV Infections
Interventions
Zalcitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Nutley, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone to Treat Fatty Liver in People With HIV Infection

NCT00441272
View directory record Official record
Conditions
HIV Infections, Hepatic Steatosis, Insulin Resistance
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2010 · Synced Oct 10, 2026, 4:05 PM EDT
Not listed Not applicable Interventional

Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

NCT01969461
View directory record Official record
Conditions
HIV
Interventions
Motivational Enhancement Therapy (MET)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 24 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating HIV and Hepatitis C Screening in an Urban Emergency Department

NCT03252483
View directory record Official record
Conditions
Hepatitis C, Hiv, HIV/AIDS, HCV Coinfection, HIV/AIDS and Infections
Interventions
Bundled HCV/HIV Screening, HIV Screening
Other
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 4 Interventional Results available

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

NCT00757783
View directory record Official record
Conditions
HIV
Interventions
ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF], atazanavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years to 99 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
15
States / cities
Los Angeles, California • Glastonbury, Connecticut • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 10, 2026, 4:05 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Combined Injectable Treatment for HIV and OUD

NCT05991622
View directory record Official record
Conditions
Human Immunodeficiency Virus, Opioid Use Disorder
Interventions
Combined LAI Treatment: Cabenuva and Sublocade
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 10, 2026, 4:05 PM EDT
Enrolling by invitation No phase listed Observational

Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening Accuracies

NCT06144229
View directory record Official record
Conditions
Hiv, Hpv
Interventions
Self-Collection HPV testing kit from Abbott
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

NCT00201123
View directory record Official record
Conditions
Tuberculosis, AIDS-related Complex
Interventions
Aerosol Interferon-Gamma, Subcutaneous interferon-gamma, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 10, 2026, 4:05 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 10, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

A Study of PMPA in HIV-Infected Patients

NCT00002180
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 4:05 PM EDT
Terminated No phase listed Observational

Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility

NCT00692783
View directory record Official record
Conditions
Candidiasis, HIV Infections
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 10, 2026, 4:05 PM EDT